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Objectives. Evidence from case-control studies as well as meta-analyses of these study 
designs suggest elevated lipoprotein(a) [Lp(a)] to be associated with an increased risk of 
venous thromboembolism (VTE). Prospective evidence on the association is limited, 
uncertain, and could be attributed to regression dilution bias. We aimed to assess the 
prospective association of Lp(a) with risk of VTE and correct for regression dilution. Design. 
We related plasma Lp(a) concentrations to the incidence of VTE in 2,180 men of the Kuopio 
Ischemic Heart Disease cohort study. Hazard ratios (HRs) (95% confidence intervals [CI]) 
were assessed and repeat measurements of Lp(a) at 4 and 11 years from baseline, were used 
to correct for within-person variability. Results. After a median follow-up of 24.9 years, 110 
validated VTE cases were recorded. The regression dilution ratio of loge Lp(a) adjusted for 
age was 0.85 (95% CI: 0.82-0.89). In analyses adjusted for several established risk factors and 
potential confounders, the HR (95% CI) for VTE per 1 SD (equivalent to 3.56-fold) higher 
baseline loge Lp(a) was 1.06 (0.87-1.30). In pooled analysis of five population-based cohort 
studies (including the current study) comprising 66,583 participants and 1,314 VTE cases, the 
fully-adjusted corresponding HR for VTE was 1.00 (95% CI: 0.94-1.07), with no evidence of 
heterogeneity between studies. Conclusions. Primary analysis as well as pooled evidence 
from previous studies suggest circulating Lp(a) is not prospectively associated with future 
VTE risk, indicating that evidence of associations demonstrated in case-control designs may 
be driven by biases such as selection bias. 
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Lipoprotein (a) [Lp(a)], composed of a dual structure and has both proatherosclerotic and 
prothrombotic functions [1,2], is an enigmatic lipoprotein that has been the subject of research 
over the past two decades. The relationship existing between Lp(a) and cardiovascular disease 
(CVD) has been well established. Consistently, several well-designed large-scale 
epidemiological studies have shown Lp(a) to be independently associated with cardiovascular 
outcomes [3-6] with some suggestions of causal relationships reported [4-6]. Though Lp(a) 
pathophysiology in vascular disease is controversial and still not fully understood, evidence 
suggests that Lp(a) contributes to the aetiology of vascular diseases via proatherosclerotic and 
proinflammatory mechanisms [7]. Venous thromboembolism (VTE) (comprising deep  vein 
thrombosis (DVT) and pulmonary embolism (PE)), which is an important cause of increased 
morbidity and premature mortality [8,9], is closely linked with CVD [10-12] and both 
conditions share common antecedent risk factors [13]. Given the prothrombotic properties of 
Lp(a), it has been suggested that Lp(a) may play a role in the pathophysiology of VTE. 
Indeed, emerging data supports an association between elevated Lp(a) and VTE risk. Several 
case-control studies have shown increased VTE risk with elevated Lp(a) concentrations [14-
17]. Two meta-analyses of these study designs have also confirmed these associations 
[18,19]. It appears the data showing a relationship between Lp(a) and VTE have largely been 
based on case-control designs, which are characterised by selection bias and do not show a 
temporal relationship between Lp(a) and VTE risk. A number of prospective cohort studies 
based in the general population have consistently reported no evidence of an association 
between Lp(a) and future VTE risk [20,21].  
Based on the emerging data, it appears Lp(a) might not be prospectively linked to VTE 
risk, however more research is needed given that incident VTE rates in these previous studies 
were relatively small. Furthermore, there is a possibility that the inability of previous long-
term follow-up cohort studies to demonstrate an association between Lp(a) and VTE risk 
could be partly attributed to regression dilution bias [22]. This is a phenomenon which 
potentially results in the underestimation of the true association between an exposure (Lp(a) 
 
 
and outcome (VTE), particularly for cohorts with long-term follow-up. Regression dilution 
bias can be addressed by correcting the risk estimates using the regression dilution ratio 
(RDR) [23].  
Due to the wide uncertainty in the evidence, we sought to evaluate in detail the prospective 
nature of the association between Lp(a) and future VTE risk using a population-based cohort 
of 2,180 men from eastern Finland followed up for over of 20 years. Secondly, repeat 
measurements of Lp(a) performed several years apart in a random sample of participants 
enabled quantification of within-person variability in Lp(a) levels. We also performed pooled 
analysis of available published prospective evidence on the association, thereby offering the 
opportunity to re-evaluate the nature and magnitude of the association in a larger 
representative sample of participants and VTE cases. 
 
Methods 
Study design and population 
This study was conducted in accordance with STROBE (STrengthening the Reporting of 
OBservational studies in Epidemiology) guidelines for reporting observational studies in 
epidemiology (Appendix A) [24]. The study population is based on the Kuopio Ischemic 
Heart Disease (KIHD) risk factor study, a general population-based prospective cohort study 
designed to investigate risk factors for CVD and other chronic diseases. The design and 
recruitment methods of the KIHD study have been described in previous reports [25-30]. 
Participants consisted of a representative sample of men aged 42-61 years who were 
inhabitants of the city of Kuopio and its surrounding rural communities in eastern Finland. 
The actual baseline cohort consisted of 2,682 participants had baseline measurements 
performed between March 1984 and December 1989. In the current analysis, complete 
information on plasma Lp(a), relevant covariates, and VTE outcomes was available for 2,180 
men. The research protocol was approved by the institutional review board of the University 
of Eastern Finland. All study procedures were conducted according to the Declaration of 
Helsinki. Written informed consent was obtained from all participants  
 
 
Assessment of Lp(a) and other risk markers 
Assessment of data on demographics, lifestyle characteristics, physical measurements, 
collection of blood samples and measurement of serum lipids, lipoproteins and biochemical 
analytes have been described in previous reports [27,29]. Blood samples were taken between 
8 and 10 a.m. after an overnight fast. The cholesterol content of lipoprotein fractions were 
measured from fresh samples after combined ultracentrifugation and precipitation, and were 
assessed enzymatically (Boehringer Mannheim, Mannheim, Germany) [31]. Lp(a) 
measurements were made from frozen plasma samples stored at -20° C for 2-6 years, using  a 
radioimmunoassay (Mercodia Apo(a) RIA, Mercodia AB, Uppsala, Sweden), with repeat 
measurements performed in a random subset of participants at 4 years and 11 years after the 
baseline measurements. Fasting plasma glucose (FPG) was measured by the glucose 
dehydrogenase method (Merck, Darmstadt, Germany). Serum high sensitivity C-reactive 
protein (hsCRP) measurements were made with an immunometric assay (Immulite High 
Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, USA). Plasma fibrinogen 
concentrations were determined in fresh plasma samples with excess thrombin using the 
Coagulometer KC4 device (Heinrich Amelung GmbH, Lemgo, Germany). For the 
assessments of age, lifestyle factors such as smoking and alcohol consumption, medical 
conditions, and medication history; participants completed self-administered questionnaires 
[32]. The energy expenditure of physical activity was assessed using the validated KIHD 12-
month leisure-time physical activity questionnaire [33,34]. Body mass index (BMI) was 
estimated as weight in kilograms divided by the square of height in meters. 
 
Ascertainment of incident VTE 
We included all first lifetime VTE events that occurred from study enrollment through to 
2013. These were identified by computer linkage to the National Hospital Discharge Registry 
data and a comprehensive review of available hospital records, wards of health centres, health 
practitioner questionnaires, death certificate and autopsy registers, and medico-legal reports. 
The diagnosis of DVT or PE required positive imaging tests. Documents were cross-checked 
 
 
in detail and VTE events were validated by two physicians. No losses to follow-up were 
recorded as all participants in the KIHD study (using Finnish personal identification codes) 
are under continuous surveillance for the development of new outcomes including VTE cases.  
 
Statistical analysis 
Prospective cohort analyses Skewed variables (hsCRP, triglycerides, and fibrinogen) were 
log transformed to achieve approximately symmetrical distributions. Descriptive analyses 
were conducted to summarize the baseline characteristics of the participants, with means 
(standard deviation, SD) or medians (interquartile range, IQR) reported for continuous 
variables and n (percentages) for categorical variables. The partial correlation coefficients 
were calculated using linear regression models adjusted for age, to assess the cross-sectional 
associations of Lp(a) with various risk markers. The SD of baseline loge Lp(a) concentration 
was 1.27, corresponding to approximately four-fold higher circulating Lp(a) (ie, e1.27=3.56). 
Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox 
proportional hazard models, after confirming no major departure from the assumptions of 
proportionality of hazards using Schoenfeld residuals.[35] Lp(a) was modelled continuously 
(per1 SD (ie, 3.56 fold) higher Lp(a) levels) and by quartiles defined according to the baseline 
distribution of plasma Lp(a) levels. Hazard ratios were calculated with adjustment for 
confounders in two models: i) age and ii) established risk factors and other potential 
confounders [BMI, systolic blood pressure (SBP), history of hypertension, prevalent coronary 
heart disease (CHD), smoking status, history of diabetes, total cholesterol, lipid lowering 
medication, estimated glomerular filtration rate (eGFR) as calculated using the Chronic 
Kidney Disease Epidemiology Collaboration formula [36], physical activity, alcohol 
consumption, prevalent cancer, fibrinogen and hsCRP. We employed formal tests of 
interaction to assess statistical evidence of effect modification on the association by 
categories of pre-specified clinically relevant individual level characteristics. To quantify and 
correct for within-person variability in Lp(a) levels, which is, the extent to which an 
individual’s Lp(a) measurements vary around the long-term average exposure levels (“usual 
 
 
levels”) [37], adjusted regression dilution ratios (RDRs) were calculated by regressing 
available repeat measurements of Lp(a) on baseline values [23]. The RDR assumes that the 
“usual levels” of Lp(a) represents the true long-term exposure of Lp(a) levels on VTE risk.  
 
Systematic review and meta-analysis We conducted a meta-analysis of published prospective 
cohort studies reporting on the association between Lp(a) and risk of VTE, using a predefined 
protocol and reported in accordance with PRISMA and MOOSE guidelines [38,39] 
(Appendix B and C). Published observational population-based prospective (cohort, case 
cohort, or nested case-control) studies that evaluated the associations between baseline levels 
of Lp(a) and risk of first VTE in the adult general population up to July 2018, were sought 
using computer-based databases (MEDLINE, EMBASE, and Web of Science). Case-control 
study designs were not part of the inclusion criteria. The computer-based searches combined 
free and MeSH search terms and combined key words related to the exposure (e.g., 
“lipoprotein(a)”) and outcome (e.g., “venous thromboembolism”, “deep vein thrombosis”, 
“pulmonary embolism”). We placed no restrictions on language or the publication date. 
Details of the search strategy are reported in Appendix D. We assessed study quality using 
the nine-star Newcastle–Ottawa Scale (NOS)[40] as described previously [41]. Summary 
measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). 
Following Cornfield’s rare disease assumption [42], hazard ratios and odds ratios were 
assumed to approximate the same measure of RR. To enable a consistent approach to the 
meta-analysis and enhance comparison with the primary analysis, reported study-specific risk 
estimates were also transformed to per SD increase in Lp(a) or as extreme quartiles of Lp(a) 
using standard statistical methods [43,44], which have been described in detail previously 
[45,46]. Summary RRs were pooled using a random effects model to minimize the effect of 
between-study heterogeneity [47]. Subsidiary analysis used fixed effects models. Statistical 
heterogeneity between studies was quantified using standard chi-square tests and the I2 
statistic [48].  All statistical analyses were conducted using Stata version 15 (Stata Corp, 





Baseline characteristics of Lp(a) and correction for within-person variability 
The mean baseline age of study participants was 53 (SD, 5) years and the median (IQR) of 
Lp(a) at baseline was 9.66 (3.75-22.27) mg/dl (Table 1). Plasma Lp(a) levels were weakly 
correlated with several risk markers. There were inverse correlations of Lp(a) with BMI, 
triglycerides, and FPG; whereas, positive correlations were observed for total cholesterol, 
creatinine, fibrinogen, and hsCRP. Repeat measurements of Lp(a) taken 4 years and 11 years 
after baseline were available in a random sample of 691 men, providing a total of 1,360 repeat 
measurements of Lp(a). Overall, the regression RDR of loge Lp(a), adjusted for age, was 0.85 
(95% CI: 0.82 to 0.89), suggesting that the associations using baseline measurements of Lp(a) 
with VTE would under-estimate the association by [(1/0.85)-1]*100=18%. 
 
Lipoprotein(a) and risk of VTE 
Prospective cohort results During a median follow-up of 24.9 (interquartile range, 17.9-27.1) 
years, 110 VTE cases (annual rate 2.32/1,000 person-years at risk; 95% CI: 1.93 to 2.80) were 
recorded. The HR per 1 SD change in baseline loge Lp(a) concentration was 1.06 (95% CI: 
0.88 to 1.29; p=0.530) in age-adjusted analysis, which remained consistent on further 
adjustment for several established risk factors and potential confounders 1.06 (95% CI: 0.87 
to 1.30; p=0.537) (Table 2). The null associations were maintained in analyses by quartiles of 
the baseline distribution of Lp(a) levels (Table 2). The findings were also similar on 
correction for regression dilution (Table 2). In further analysis that compared Lp(a) 
concentrations > 30 mg/dl with that ≤ 30 mg/dl, no evidence of any association was observed. 
Hazard ratios did not vary importantly by several relevant clinical characteristics (Figure 1).  
 
Meta-analysis of published studies We identified four population-based prospective cohort 
studies reporting on the associations between circulating Lp(a) and VTE risk (Appendices E 
and F).[20,21,49,50] Including the current study, the pooled analysis involved five studies 
 
 
comprising 66,583 participants and 1,314 VTE cases. The pooled RR for VTE per 1 SD 
higher baseline loge Lp(a) in fully-adjusted analyses was 1.00 (95% CI: 0.94 to 1.07) (I
2=0%, 
95% CI: 0 to 79%; P=0.576) (Figure 2). The corresponding RR was 1.00 (95% CI: 0.84 to 
1.19) when comparing the top versus bottom quartiles of Lp(a) levels. When a fixed effect 




Summary of main findings 
In this population-based prospective study of middle-aged men without a history of VTE at 
study entry, our analysis showed no evidence of an association of circulating Lp(a) with risk 
of VTE. The association did also not vary importantly across several clinically relevant 
subgroups. Our reproducibility studies of Lp(a) yielded a high RDR which indicates that 
Lp(a) concentration is consistent within individuals over several years. Pooled estimates of 
five prospective studies (including the current study) confirmed our finding of no evidence of 
an association in the primary cohort analysis and there was no evidence of heterogeneity 
between the contributing studies. 
 
Comparison with previous work  
Several reports based on case-control designs have reported on the associations between 
circulating Lp(a) and VTE risk. Though the findings from these reports have been mixed, 
majority have generally shown an increased risk of VTE with elevated Lp(a) [14-17]. There 
have also been efforts to aggregate these data resulting in two published reviews on the topic. 
In the earlier review, Sofi and colleagues pooled the results of six case-control studies and 
showed a significant association between high Lp(a) levels and VTE risk [18]. In a more 
recent review, Dentali and colleagues pooled the results of 14 studies and also demonstrated 
Lp(a) to be associated with an increased risk of VTE [19]. Of all 14 studies included in this 
review, only one prospective cohort was included and this was the study conducted by 
 
 
Kamstrup et al [20]. Indeed, data showing evidence of an association between circulating 
Lp(a) and VTE risk seems to be based on case-control study designs. Unfortunately, these 
study designs are characterised by selection bias and are not able to adequately address 
temporality. Prior to the current study, four large-scale prospective cohort studies based in the 
general population and with long-term follow-up for VTE events have all consistently shown 
that circulating Lp(a) is not associated with VTE risk [20,21,49,50]. Though these previous 
studies did not correct for regression dilution bias, our current analysis shows that risk 
estimates based on baseline and repeated measures corresponded well. Results from the 
KIHD prospective study as well as pooled analysis of available prospective evidence indicate 
that Lp(a) is not associated with risk of VTE. 
 
Possible explanations for findings 
As with all observational cohort studies, exposure or risk factor levels are usually assessed at 
study entry and related to outcomes which occur after several years. However, due to random 
measurement errors, temporary fluctuations and changes in the exposure over time, the effect 
and value of the exposure changes with time leading to regression dilution bias [22]. This 
potentially results in the underestimation of the true association between an exposure and 
outcome, particularly for cohorts with long-term follow-up. It can be argued that the absence 
of an association between Lp(a) and VTE in previous cohorts could be potentially explained 
by the phenomenon of regression dilution. However, this is unlikely given that we found no 
evidence of an association despite correcting for regression dilution. Furthermore, 
reproducibility substudies of Lp(a) in the KIHD and that of other large-scale cohort studies[3] 
indicate that analyses using only single baseline measurements of Lp(a) does not 
underestimate the associations between Lp(a) and outcomes. There is established evidence 
that Lp(a) is associated with CVD outcomes and it has been suggested that the 
pathophysiological mechanisms underlying the associations may relate to the pro-atherogenic, 
prothrombotic, and pro-inflammatory properties of Lp(a) [7]. Given the prothrombotic and 
antifibrinolytic properties of Lp(a) [2], the closely linked nature of CVD and VTE [10-12], 
 
 
and the emerging evidence from both epidemiological and clinical studies; there is a growing 
debate that Lp(a) may also be linked to the development of VTE. The current data which is 
based on prospective evidence does not support this suggestion and it is possible that Lp(a) 
may not be an emerging risk factor for VTE. Spence and Koschinsky also argue that the 
effects of Lp(a) on VTE risk may only be evident at the highest concentrations of Lp(a) [51], 
which we were not able to prove in the current study. However, mechanistic conclusions 
underlying the association between Lp(a) and VTE cannot be drawn from observational 
epidemiological studies and further studies on mechanisms are warranted. 
 
Strengths and limitations  
Compared to previous prospective cohort studies, the current study had the advantage of 
being a well-characterised cohort of men who were nationally representative; involved a high 
response rate, a long-follow-up period of over 20 years with no loss to follow-up; and 
comprehensive analysis with adjustment for a broad panel of lifestyle and biological markers 
as well as stratified analyses by several clinical relevant characteristics. An important strength 
of the current study is that repeat measurements of Lp(a) made within a random subset of 
individuals over time after baseline were available, which enabled correction for the extent of 
within-person variability in Lp(a) over the long period of follow-up. Finally, we were able to 
conduct a pooled analysis of previous studies including the current study, to put the findings 
into wider context. In our pooled analysis, there was no evidence of heterogeneity between 
contributing studies. Our study was characterized by the following limitations: (i) we included 
only middle-aged men based on a predominantly white-European population from eastern 
Finland and given that plasma levels of Lp(a) may vary substantially between different 
populations [52], our findings therefore cannot be generalized to women, the young, and other 
ethnicities; (ii) we had data on only all VTEs which precluded the ability to conduct subgroup 
analyses of type of specific VTE outcomes such as idiopathic VTE or that due to cancer; and 
(iii) inability to adjust for other potential confounders such incident cancer, family history of 





Primary cohort analysis as well as pooled evidence from previous studies suggest that 
circulating Lp(a) is not prospectively associated with future VTE risk. This comprehensive 
report indicates that the associations demonstrated in previous studies may be driven by 
features and limitations of study designs employed. 
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Mean (SD) or 




Quartile 1  
Mean (SD) or 




Quartile 2  
Mean (SD) or 




Quartile 3  
Mean (SD) or 




Quartile 4  
Mean (SD) or 






r (95% CI)† 
Lipoprotein(a) (mg/dl) 9.66 (3.75-22.27) 1.61 (0.90-2.73) 6.23 (4.88-7.84) 15.0 (12.3-18.5) 36.8 (28.5-51.8) - 
       
Questionnaire/Prevalent 
conditions 
      
Age at survey (years) 53 (5) 53 (5) 53 (5) 53 (5) 53 (5) 0.01 (-0.03, 0.05) 
Alcohol consumption (g/week) 31.9 (6.4-92.8) 30.1 (6.4-96.0) 28.4 (6.1-88.4) 32.9 (6.1-96.9) 35.5 (7.6-88.5) -0.00 (-0.05, 0.04) 
History of diabetes 87 (4.0) 31 (5.7) 26 (4.8) 20 (3.7) 10 (1.8) - 
Current smokers 669 (30.7) 161 (29.5) 165 (30.2) 168 (30.9) 175 (32.1) - 
History of hypertension 653 (30.0) 178 (32.7) 162 (29.7) 148 (27.2) 165 (30.3) - 
History of CHD 546 (25.1) 157 (28.8) 131 (24.0) 122 (22.4) 136 (25.0) - 
History of cancer 36 (1.7) 11 (2.0) 11 (2.0) 7 (1.3) 7 (1.3) - 
Lipid lowering medication 14 (0.6) 5 (0.9) 2 (0.4) 1 (0.2) 6 (1.1) - 
       
Physical measurements       
BMI (kg/m2) 26.9 (3.5) 27.6 (3.9) 26.7 (3.4) 26.8 (3.3) 26.6 (3.4) -0.10 (-0.14, -0.06)*** 
SBP (mmHg) 134 (17) 135 (17) 133 (16) 134 (17) 133 (17) -0.04 (-0.08, -0.00) 
DBP (mmHg) 89 (10) 89 (11) 88 (10) 89 (11) 88 (10) -0.04 (-0.08, 0.00) 
Physical activity (kj/day) 1192 (621-1987) 1231 (662-1991) 1160 (669-1998) 1104 (58.-1891) 1275 (612-2021) -0.03 (-0.07, 0.02) 
       
Lipid markers       
Total cholesterol (mmol/l) 5.91 (1.08) 5.73 (1.02) 5.88 (1.09) 5.88 (1.12) 6.12 (1.05) 0.12 (0.08, 0.16)*** 
HDL-C (mmol/l) 1.30 (0.30) 1.31 (0.32) 1.30 (0.28) 1.30 (0.30) 1.29 (0.30) -0.01 (-0.05, 0.03) 
Triglycerides (mmol/l) 1.10 (0.81-1.56) 1.15 (0.84-1.68) 1.08 (0.78-1.58) 1.10 (0.82-1.52) 1.10 (0.79-1.55) -0.06 (-0.10, -0.02)* 
       
Metabolic, renal, and 
inflammatory markers 
      
Fasting plasma glucose (mmol/l) 5.35 (1.26) 5.50 (1.52) 5.34 (1.20) 5.34 (1.19) 5.23 (1.07) -0.07 (-0.11, -0.03)** 
Serum creatinine (µmol/1) 89.4 (13.7) 88.6 (12.1) 89.1 (13.5) 89.0 (14.9) 91.0 (14.0) 0.04 (0.00, 0.08)* 
Estimated GFR (ml/min/1.73 m2) 86.9 (17.1) 87.4 (15.0) 87.7 (20.5) 87.5 (16.2) 85.2 (16.2) -0.03 (-0.08, 0.01) 
Fibrinogen (g/l) 2.96 (2.63-3.33) 2.91 (2.58-3.28) 2.95 (2.63-3.31) 2.97 (2.68-3.32) 3.00 (2.67-3.44) 0.08 (0.03, 0.12)** 
High sensitivity CRP (mg/l) 1.27 (0.70-2.38) 1.17 (0.61-2.25) 1.20 (0.65-2.34) 1.34 (0.76-2.37) 1.35 (0.80-2.73) 0.09 (0.05, 0.13)*** 
 
BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; Lp(a), 
lipoprotein(a) 
HDL-C, high-density lipoprotein cholesterol; KIHD, Kuopio Ischemic Heart Disease; SD, standard deviation; SBP, systolic 
blood pressure;  
VTE, venous thromboembolism; asterisks indicate the level of statistical  
significance: *, p<0.05; **, p<0.01; ***, p<0.001, †Pearson correlation coefficients  






Table 2. Association of Lp(a) and venous thromboembolism in the KIHD cohort 
 




Model 1 Model 2 
   HR (95% CI) HR (95% CI) 
 Baseline Lp(a) 
Per 1 SD increase in log 
Lp(a) 
110 / 2,180 47,400 1.06 (0.88 to 1.29) 1.06 (0.87 to 1.30) 
Q1 (0.56-3.74) 25 / 545 11,810 ref ref 
Q2 (3.75-9.66) 30 / 546 11,980 1.19 (0.70 to 2.03) 1.24 (0.72 to 2.12) 
Q3 (9.67-22.26) 25 / 544 11,914 0.99 (0.57 to 1.72) 1.02 (0.58 to 1.79) 
Q4 (> 22.26) 30 / 545 11,695 1.23 (0.72 to 2.09) 1.25 (0.72 to 2.15) 
 Usual Lp(a)* 
Per 1 SD increase in log 
Lp(a) 
110 / 2,180 47,400 1.07 (0.86 to 1.35) 1.08 (0.85 to 1.36) 
Q1 (0.56-3.74) 25 / 545 11,810 ref ref 
Q2 (3.75-9.66) 30 / 546 11,980 1.23 (0.66 to 2.30) 1.29 (0.68 to 2.42) 
Q3 (9.67-22.26) 25 / 544 11,914 0.98 (0.51 to 1.89) 1.02 (0.52 to 1.98) 
Q4 (> 22.26) 30 / 545 11,695 1.28 (0.68 to 2.38) 1.29 (0.68 to 2.47) 
 
CI, confidence interval; HR, hazard ratio; KIHD, Kuopio Ischemic Heart Disease; Lp(a), lipoprotein(a); Q, 
quartile; ref, reference; SD, standard deviation;  
*, indicates correction for within-person variability in values of Lp(a), that is, the extent to which an individual’s 
Lp(a) measurements vary around a long-term average value (“usual Lp(a) values”); the SD of loge Lp(a) 
concentration is 1.27, corresponding to approximately four-fold higher circulating Lp(a) (ie, e1.27=3.56) 
Model 1: Adjusted for age  
Model 2: Model 1 plus body mass index, systolic blood pressure, history of hypertension, prevalent coronary heart 
disease, smoking status, history of diabetes, total cholesterol, triglycerides, lipid medication, estimated glomerular 






Figure 1. Hazard ratios for baseline levels of lipoprotein(a) and venous thromboembolism 
risk by several participant level characteristics in the KIHD cohort 
Age at survey (years)
< 54.4
≥ 54.4
Body mass index (kg/m2)
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1.2 .4 .6 2 4 8 16 32
HR (95% CI) per 1SD change in loge Lp(a)
 
Hazard ratios are reported per 1 standard deviation increase in loge lipoprotein(a); hazard ratios were adjusted for age, body mass 
index, systolic blood pressure, history of hypertension, prevalent coronary heart disease, smoking status, history of diabetes, total 
cholesterol, triglycerides, lipid medication, estimated glomerular filtration rate, physical activity, alcohol consumption, prevalent 
cancer, fibrinogen, and high sensitivity C-reactive protein; CHD, coronary heart disease; CI, confidence interval; GFR, 
glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; KIHD, Kuopio Ischemic Heart Disease; Lp(a), 
lipoprotein(a); SD, standard deviation; *, P-value for interaction 
 
 
































HR (95% CI) per 1 SD higher log baseline Lp(a) levels
 
The summary estimates presented were calculated using random effects models; relative risks are reported per 1 standard 
deviation (SD) increase in lipoprotein(a); sizes of data markers are proportional to the inverse of the variance of the relative ratio; 
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 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
Page 1 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Page 3-4 
Objectives 3 State specific objectives, including any pre-specified hypotheses Page 3-4 
Methods  
Study design 4 Present key elements of study design early in the paper Study design 
and population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 




Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 




(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
Assessment of 





8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
Assessment of 
Lp(a) and other 
risk markers 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical 
analysis 
 





11 Explain how quantitative variables were handled in the analyses. If applicable, 









(b) Describe any methods used to examine subgroups and interactions Statistical 
analysis 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 





Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in the 





  (b) Give reasons for non-participation at each stage Study design 
and population 
  (c) Consider use of a flow diagram Not applicable 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
Results; Table 1  
  (b) Indicate number of participants with missing data for each variable of 
interest 
 
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which 
confounders were adjusted for and why they were included 
Results; Table 2 
  (b) Report category boundaries when continuous variables were categorized Results; Table 2 
  (c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period 
 





   
Key results 18 Summarise key results with reference to study objectives Discussion - 
Summary of 
main findings 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present study and, 









No Checklist item 
Reported 
on page No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data 
sources, study eligibility criteria, participants, interventions, study appraisal and synthesis 
methods, results, limitations, conclusions and implications of key findings, systematic 
review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 4 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), 




6 Specify study characteristics (such as PICOS, length of follow-up) and report 
characteristics (such as years considered, language, publication status) used as criteria for 




7 Describe all information sources (such as databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated 
Appendix D 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic 




10 Describe method of data extraction from reports (such as piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) 
and any assumptions and simplifications made 
Methods 
Risk of bias in 
individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 




13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as 




16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 




18 For each study, present characteristics for which data were extracted (such as study size, 
PICOS, follow-up period) and provide the citations 
Appendix F 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment 





20 For all outcomes considered (benefits or harms), present for each study (a) simple 
summary data for each intervention group and (b) effect estimates and confidence 








Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional 
analysis 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-





24 Summarise the main findings including the strength of evidence for each main outcome; 







No Checklist item 
Reported 
on page No 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level 
(such as incomplete retrieval of identified research, reporting bias) 
Discussion 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research 
Discussion 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of 




Appendix C. MOOSE checklist  
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Elevated circulating lipoprotein(a) has been suggested to the linked to 
the development of venous thromboembolism (VTE), but the 
prospective nature of the association is uncertain. 
 Hypothesis statement There is no prospective association between Lp(a) and VTE risk.  
 Description of study outcomes VTE 
 Type of exposure  Blood levels of Lp(a) 
 Type of study designs used Prospective (cohort, case-cohort or “nested case control”) population-
based studies 
 Study population Approximately general populations with no prevalent VTE at 
baseline 
Reporting of search strategy should 
include 
 
 Qualifications of searchers Setor Kunutsor, MD PhD; Jari Laukkanen, MD 
 Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE, EMBASE, Web of 
Science to 18 July 2018.  
Search strategy: 
In Appendix 4. 
 
 Databases and registries searched MEDLINE, EMBASE, and Web of Science 
 Search software used, name and 
version, including special features 
Ovid was used to search EMBASE 
Endnote used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
 Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
 Method of handling abstracts and 
unpublished studies 
None found 
 Description of any contact with 
authors 
Not applicable 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels and performed sub-group analyses to 
evaluate differences in the overall estimates according to levels of 
adjustment. 
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
on possible predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa 
Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome. Sensitivity analyses by several quality 
indicators such as study size, duration of follow-up, and adjustment 
factors. 
 Assessment of heterogeneity Heterogeneity of the studies was explored with I2 statistic that 
provides the relative amount of variance of the summary effect due to 
the between-study heterogeneity. 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses are detailed in the methods. 
We performed random effects meta-analysis with Stata 15. 
 
 
 Provision of appropriate tables and 
graphics 
Figure 2 and Appendix F 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figure 2 
 Table giving descriptive information 
for each study included 
Appendix F 
 Results of sensitivity testing 
 
Not applicable 
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, 
I2 values and results of sensitivity analyses 
Reporting of discussion should include  
 Quantitative assessment of bias There was no evidence of heterogeneity between contributing studies. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
 Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative 
explanations for observed results 
Discussed in the context of the results. 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research Assessment of the mechanistic pathways underlying the link between 
Lp(a) and VTE 




Appendix D. Literature search strategy 
Relevant studies published before 18 July, 2018 (date last searched), were identified through electronic 
searches not limited to the English language using MEDLINE, EMBASE, and the Science Citation 
Index databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles) and by hand searching of relevant journals. 
The computer-based searches combined search terms related to lipoprotein(a) and venous 
thromboembolism without language restriction. 
 
1     exp "Lipoprotein(a)"/ (4776) 
2     exp Venous Thromboembolism/ (8367) 
3     exp Venous Thrombosis/ (51541) 
4     exp Pulmonary Embolism/ (36297) 
5     2 or 3 or 4 (86213) 
6     1 and 5 (79) 
7     limit 6 to humans (79) 
 
Parts i, ii and iii were combined using ‘AND’ to search MEDLINE. Each part was specifically 





Appendix E. Flow of studies included in pooled analysis 
 
 
663 Potentially relevant citations identified
from MEDLINE, EMBASE, Web of Science, 
and reference list of relevant studies
651 Articles excluded on the 
basis of title and/ or abstract
8 Articles excluded due to:
6 study designs not relevant
1 outcome not relevant
1 duplicate
4 Articles included, based on 4
unique studies


































Appendix F. Characteristics of prospective studies included in meta-analysis 
 
 
Lead author, publication year 
[Reference] 
 
Name of study 
 































           
Tsai, 2002 [21] LITE USA 1987-1998 59.0 45.0 8.0 19,293 215 Age, race, and sex 8 
Kamstrup, 2012 [20] CCHS Denmark 1991-1994 58.0 44.0 13.0 9,138 440 Age, sex, BMI, smoking, physical activity, menopausal 
status, HRT, oral contraceptives 
9 
van Schouwenburg, 2012 [50] PREVEND Netherlands 1997-1998 49.0 49.0 10.5 7,627 110 Age, sex, hypertension, DM, CRP, BMI, eGFR, smoking 7 
Danik, 2013 [49] WHS USA 1992-1995 54.2 0.0 14.4 28,345 439 Age, smoking, BMI, hormone therapy status, exercise 
level and randomization treatment arms 
7 
Current study, 2018 KIHD Finland 1984-1989 42-61 100.0 24.9 2,180 110 Age, BMI, SBP, history of hypertension, prevalent CHD, 
smoking, history of DM, total cholesterol, Triglycerides, 
lipid medication, eGFR, physical activity, alcohol 
consumption, prevalent cancer, fibrinogen, hsCRP 
8 
Total       66,583 1,314   
 
BMI, body mass index; CHD, coronary heart disease; CCHS, Copenhagen City Heart Study; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HRT, hormone 
replacement therapy; hsCRP, high sensitivity C-reactive protein; KIHD, Kuopio Ischemic Heart Disease; LITE, The Longitudinal Investigation of Thromboembolism Etiology; 
NR, not reported; PREVEND, Prevention of Renal and Vascular End-stage Disease; SBP, systolic blood pressure; WHS, Women’s Health Study 
 
 
 
